Search

Your search keyword '"Velaga, Swetha Bindu"' showing total 29 results
Start Over Author "Velaga, Swetha Bindu"
29 results on '"Velaga, Swetha Bindu"'

1. The relationship of diabetic retinopathy severity scales with frequency and surface area of diabetic retinopathy lesions

Author

Esmaeilkhanian, Houri, Liu, Henry, Fasih-Ahmed, Sohaib, Gnanaraj, Ramya, Verma, Aditya, Oncel, Deniz, He, Ye, Nittala, Muneeswar Gupta, Attiku, Yamini, Kadomoto, Shin, Corradetti, Giulia, Velaga, Swetha Bindu, Tsui, Irena, Prasad, Pradeep, Li, Xiaorong, Li, Xiao, Jiang, Shangjun Collier, Choudhry, Netan, Jayadev, Chaitra, and Sadda, SriniVas

Published
2023
Full Text
View/download PDF

6. Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial

Author

Wykoff, Charles C., Nittala, Muneeswar G., Zhou, Brenda, Fan, Wenying, Velaga, Swetha Bindu, Rusakevich, Alexander M., Lampen, Shaun I.R., Ip, Michael S., Sadda, SriniVas R., Ehlers, Justis P., Srivastava, Sunil K., Reese, Jamie L., Babiuch, Amy, Talcott, Katherine, Figueiredo, Natalia, Hach, Jenna, Ou, William C., Fish, Richard H., Benz, Matthew S., Chen, Eric, Kim, Rosa Y., Major, James C., Jr., O’Malley, Ronan E., Brown, David M., Shah, Ankoor R., Schefler, Amy C., Wong, Tien P., and Henry, Christopher R.

Published
2019
Full Text
View/download PDF

18. Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration

Author

Nittala, Muneeswar Gupta, primary, Metlapally, Ravi, additional, Ip, Michael, additional, Chakravarthy, Usha, additional, Holz, Frank G., additional, Staurenghi, Giovanni, additional, Waheed, Nadia, additional, Velaga, Swetha Bindu, additional, Lindenberg, Sophiana, additional, Karamat, Ayesha, additional, Koester, John, additional, Ribeiro, Ramiro, additional, and Sadda, SriniVas, additional

Published
2022
Full Text
View/download PDF

19. Final Outcomes from the Randomized RECOVERY Trial of Alfibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy

Author

Wykoff, Charles C., primary, Nittala, Muneeswar G., additional, Boone, Cecilia Villanueva, additional, Yu, Hannah J., additional, Fan, Wenying, additional, Velaga, Swetha Bindu, additional, Ehlers, Justis P., additional, Ip, Michael S., additional, Sadda, SriniVas R., additional, Wykoff, Charles C., additional, Zhou, Brenda, additional, Rusakevich, Alexander M., additional, Lampen, Shaun I.R., additional, Srivastava, Sunil K., additional, Reese, Jamie L., additional, Babiuch, Amy, additional, Talcott, Katherine, additional, Figueiredo, Natalia, additional, Hach, Jenna, additional, Ou, William C., additional, Fish, Richard H., additional, Benz, Matthew S., additional, Chen, Eric, additional, Kim, Rosa Y., additional, Major, James C., additional, O’Malley, Ronan E., additional, Brown, David M., additional, Shah, Ankoor R., additional, Schefler, Amy C., additional, Wong, Tien P., additional, and Henry, Christopher R., additional

Published
2022
Full Text
View/download PDF

20. Two-year outcomes of episcleral brachytherapy adjunct to anti-VEGF therapy for treatment-resistant nAMD.

Author

Chhablani, Jay, Jager, Rama, Ong, Joshua, Lohrenz, Ryan, Hamilton, Russell J., Stea, Baldassare, Drew, Mary, Kokame, Gregg, Doheny Retina Study Group, Gupta Nittala, Muneeswar, Lindenberg, Sophiana, Velaga, Swetha Bindu, and Karamat, Ayesha

Subjects
POLYPOIDAL choroidal vasculopathy, MACULAR degeneration, ENDOTHELIAL growth factors, RADIOISOTOPE brachytherapy, VASCULAR endothelial growth factor antagonists, THERAPEUTICS
Abstract

Purpose: This study was designed to demonstrate the safety and feasibility of episcleral brachytherapy (ESB) for the treatment of anti-vascular endothelial growth factor (anti-VEGF) resistant neovascular age-related macular degeneration (nAMD) in a 6-subject cohort adjunct to anti-VEGF therapy. Methods: Six eyes of six subjects with anti-VEGF resistant nAMD (persistent fluid or hemorrhage despite frequent anti-VEGF treatment) were treated with ESB between May 2018 and July 2018 as part of a larger early feasibility trial. Baseline and follow-up exams with multi-modal imaging were conducted. Results: In this analysis, six eyes were included. The mean age was 74.7 years; 33% were female; 67% had polypoidal choroidal vasculopathy. The mean number of lifetime anti-VEGF injections received prior to the study enrollment was 33.9 injections and 10 injections in the year prior to the study enrollment. In the first and second years following ESB, the mean number of injections was 8.5 and 8, respectively. No evidence of radiation-induced toxicity through 2 years following ESB was observed. The mean baseline VA was 55.3 letters. At 1 year, the mean VA increased by 3.2 letters and 1.7 letters at year 2. At 2 years, the mean change in vascular complex on ICGA was − 18%, − 43% on OCTA, and − 5% on FA. The subjects also experienced a mean decrease in CRT on OCT of 21% after 2 years. Conclusions: The results from this six-subject cohort with 2-year data support additional investigations of ESB for nAMD, specifically those with persistent disease activity and treatment resistant nAMD. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

23. Effect of Human Central Nervous System Stem Cell Subretinal Transplantation on Progression of Geographic Atrophy Secondary to Nonneovascular Age-Related Macular Degeneration

Author

Nittala, Muneeswar G., primary, Uji, Akihito, additional, Velaga, Swetha Bindu, additional, Hariri, Amir H., additional, Naor, Joel, additional, Birch, David G., additional, Spencer, Rand, additional, Leng, Theodore, additional, Capela, Alexandra, additional, Tsukamoto, Ann, additional, Ip, Michel, additional, and Sadda, Srinivas R., additional

Published
2021
Full Text
View/download PDF

25. Effect of Human Central Nervous System Stem Cell Subretinal Transplantation on Progression of Geographic Atrophy Secondary to Non Neovascular Age-Related Macular Degeneration

Author

Nittala, Muneeswar Gupta, primary, Uji, Akihito, additional, Velaga, Swetha Bindu, additional, Hariri, Amir H., additional, Naor, Joel, additional, Birch, David G., additional, Spencer, Rand, additional, Leng, Theodore, additional, Capela, Alexandra, additional, Tsukamoto, Ann, additional, Ip, Michel, additional, and Sadda, Srinivas, additional

Published
2019
Full Text
View/download PDF

29. Longitudinal evaluation of the distribution of intraretinal hyper-reflective foci in eyes with intermediate age-related macular degeneration.

Author

Sadda S, Verma A, Corradetti G, Nittala M, He Y, Nassisi M, Velaga SB, Haines J, Pericak-Vance M, and Stambolian D

Abstract

Purpose: Intraretinal hyper-reflective foci (IHRF) are optical coherence tomography (OCT) risk factors for progression of age-related macular degeneration (AMD). In this study we assess the change in the number and distribution of IHRF over two years., Methods: The axial distribution of IHRF were quantified in eyes with intermediate AMD (iAMD) at baseline and 24 months, using a series of 5 sequential equidistant en face OCT retinal slabs generated between the outer border of the internal limiting membrane (ILM) and the inner border of the retinal pigment epithelium (RPE). Following thresholding and binarization, IHRF were quantified in each retinal slab using ImageJ. The change in IHRF number in each slab between baseline and month 24 was calculated., Results: Fifty-two eyes showed evidence of IHRF at baseline, and all continued to show evidence of IHRF at 24 months (M24). The total average IHRF count/eye increased significantly from 4.67 ± 0.63 at baseline to 11.62 ± 13.86 at M24 (p<0.001) with a mean increase of 6.94 ± 11.12 (range: - 9 to + 60). Overall, at M24, 76.9% eyes showed an increase in IHRF whereas 15.4% of eyes showed a decrease (4 eyes [7.6%] showed no change). There was a greater number of IHRF and a greater increase in IHRF over M24 in the outer slabs., Conclusions: IHRF are most common in the outer retinal layers and tend to increase in number over time. The impact of the distribution and frequency of these IHRF on the overall progression of AMD requires further study., Competing Interests: Conflict of Interest: No conflicting relationships exist for any author.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results